NASDAQ:MGNX

MacroGenics Competitors

$31.16
-0.39 (-1.24 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.63
Now: $31.16
$31.57
50-Day Range
$18.99
MA: $28.02
$33.20
52-Week Range
$5.00
Now: $31.16
$33.61
Volume527,958 shs
Average Volume789,525 shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.4

Competitors

MacroGenics (NASDAQ:MGNX) Vs. RARE, GWPH, ASND, ARWR, TGTX, and IONS

Should you be buying MGNX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MacroGenics, including Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Ultragenyx Pharmaceutical (NASDAQ:RARE) and MacroGenics (NASDAQ:MGNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Ultragenyx Pharmaceutical and MacroGenics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
MacroGenics11902.73

Ultragenyx Pharmaceutical currently has a consensus target price of $131.20, suggesting a potential upside of 26.79%. MacroGenics has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Given Ultragenyx Pharmaceutical's higher probable upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than MacroGenics.

Insider & Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 9.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and MacroGenics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million66.80$-402,730,000.00($7.36)-14.06
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86

MacroGenics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and MacroGenics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
MacroGenics-204.31%-65.84%-49.41%

Summary

MacroGenics beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and MacroGenics (NASDAQ:MGNX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares GW Pharmaceuticals and MacroGenics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million21.94$-9,020,000.00($0.24)-908.04
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86

GW Pharmaceuticals has higher revenue and earnings than MacroGenics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for GW Pharmaceuticals and MacroGenics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
MacroGenics11902.73

GW Pharmaceuticals currently has a consensus target price of $204.0909, suggesting a potential downside of 6.35%. MacroGenics has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than GW Pharmaceuticals.

Profitability

This table compares GW Pharmaceuticals and MacroGenics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
MacroGenics-204.31%-65.84%-49.41%

Insider & Institutional Ownership

81.0% of GW Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of MacroGenics shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Summary

MacroGenics beats GW Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Valuation and Earnings

This table compares MacroGenics and Ascendis Pharma A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86
Ascendis Pharma A/S$14.98 million450.70$-244,180,000.00($5.25)-23.93

MacroGenics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MacroGenics and Ascendis Pharma A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
Ascendis Pharma A/S011102.92

MacroGenics presently has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 49.40%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than MacroGenics.

Profitability

This table compares MacroGenics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Insider and Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

MacroGenics beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Valuation and Earnings

This table compares MacroGenics and Arrowhead Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86
Arrowhead Pharmaceuticals$87.99 million73.31$-84,550,000.00($0.84)-73.99

Arrowhead Pharmaceuticals has higher revenue and earnings than MacroGenics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MacroGenics and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MacroGenics and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
Arrowhead Pharmaceuticals021002.83

MacroGenics presently has a consensus target price of $33.30, suggesting a potential upside of 6.87%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, suggesting a potential upside of 37.26%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than MacroGenics.

Risk and Volatility

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Insider and Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats MacroGenics on 10 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares MacroGenics and TG Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86
TG Therapeutics$150,000.0041,978.98$-172,870,000.00($1.83)-24.48

MacroGenics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MacroGenics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
TG Therapeutics-151,798.69%-223.96%-108.08%

Analyst Recommendations

This is a breakdown of current recommendations for MacroGenics and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
TG Therapeutics00503.00

MacroGenics presently has a consensus price target of $33.30, suggesting a potential upside of 6.87%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.89%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than MacroGenics.

Volatility and Risk

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Insider & Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

MacroGenics beats TG Therapeutics on 9 of the 14 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Valuation & Earnings

This table compares MacroGenics and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86
Ionis Pharmaceuticals$1.12 billion5.31$303.26 million$2.0820.37

Ionis Pharmaceuticals has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MacroGenics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
Ionis Pharmaceuticals7.82%6.57%3.39%

Analyst Recommendations

This is a breakdown of current recommendations for MacroGenics and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
Ionis Pharmaceuticals27602.27

MacroGenics presently has a consensus price target of $33.30, suggesting a potential upside of 6.87%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 36.71%. Given Ionis Pharmaceuticals' higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than MacroGenics.

Volatility and Risk

MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Insider & Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats MacroGenics on 8 of the 14 factors compared between the two stocks.


MacroGenics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.48-3.0%$6.93 billion$103.71 million-23.57News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.93-0.0%$6.83 billion$311.33 million-126.70Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.61-3.1%$6.75 billion$14.98 million-15.30
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.15-2.5%$6.45 billion$87.99 million-73.99News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.79-4.3%$6.30 billion$150,000.00-21.13
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.